Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783116 | 0.87 | CYP2C9 (0.54) | CYP2C9KMT2AMEN1POLBTDP1 | |
| SCHEMBL24158944 | 0.82 | CYP2C9 (0.50) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL5206489 | 0.82 | PKM (0.51) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL11063029 | 0.79 | CYP1A2 (0.55) | KMT2AMEN1POLBHDAC8TDP1 | |
| SCHEMBL28590804 | 0.79 | CYP2C9 (0.51) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL1149847 | 0.77 | CYP2C9 (0.60) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL27312350 | 0.77 | USP4 (0.51) | CYP2C9KMT2AMEN1POLBTDP1 | |
| SCHEMBL29190982 | 0.75 | GPR35 (0.37) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL15332766 | 0.75 | HDAC8 (0.36) | CYP2C9KMT2AMEN1POLBHDAC8 | |
| SCHEMBL15332233 | 0.75 | HDAC8 (0.39) | CYP2C9KMT2AMEN1POLBHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886734-A | Heterocyclic amide compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9624520-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140302553-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-10-09 | — | — | US | disclosed |
| US-8785151-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-07-22 | — | — | US | disclosed |
| EP-2356092-B1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-04-16 | — | — | EP | disclosed |
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2356092-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010048582-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2010-04-29 | — | — | WO | disclosed |
| WO-2008157273-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | PTMS, PHYKPL, DNPEP | CYP2C9 2942/4885KMT2A 1097/4885MEN1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.